Introduction {#s1}
============

The *Textbook of Rheumatology* defines osteoarthritis (OA) as a "slowly progressive monoarticular \[ ... \] disorder of unknown cause and obscure pathogenesis" affecting primarily the hands and weight-bearing joints such as hips and knees ([@B18]). It is defined clinically by joint pain, deformity, and loss of function and pathologically by articular cartilage loss and remodeling of the subchondral bone. With the advent of better imaging techniques, synovitis is being increasingly recognized as being present in a considerable proportion of cases ([@B66]; [@B74]). OA is the most common form of arthritis or degenerative joint disease; affecting millions of people ([@B5]), with the World Health Organization estimating that, globally, up to 10% of people over the age of 60 years is affected by some form of OA ([@B25]). There is currently no cure for the disease, with currently available treatment focusing on temporary symptomatic pain relief and alleviating inflammation, often leaving patients with considerable pain and functional disability. Paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids are the most prescribed pain therapies ([@B34]). Patients that do not respond to NSAIDs are candidates for opioid therapy. These therapeutic options come, however, with severe side effects: prolonged NSAID use can lead to gastrointestinal bleeding and renal toxicity and increase cardiovascular risks, and opioids are associated with constipation and potential for addiction ([@B40]). For patients with end-stage OA, surgical joint replacement is required ([@B24]). Pain management in OA continues to be one of the main focuses of research because pain is the main reason why OA patients seek medical care. However, there is currently no drug that can fully treat OA-related pain; a better understanding of the pathophysiological mechanisms in play in OA is crucial if we are to deliver better treatment options to these patients.

Animal Models of OA Pain: Surgical and Chemical Models {#s2}
======================================================

To study OA in the laboratory setting, several animal models have been developed over the last decades that contributed to a better understanding of the pathological mechanisms behind the disease. There are obvious limitations with these models, particularly those related to differences in anatomy, gait, and cartilage characteristics compared to human joints. The models only mimic parts or stages of the disease, with no model completely reproducing human OA complexity. Despite this, the use of animal models allows the study of the disease within controlled environment parameters and tissue collection at different time points of the model ([@B32]). We can divide OA animal models into two large groups---spontaneous models and induced models. Spontaneous models develop slowly but are pathophysiologically closest to human OA. However, due to the spontaneous nature of these models, it is challenging to find appropriate age-matched controls for pharmacological studies. Further, they are time- and money-consuming to produce and have a high maintenance cost.

In the second group---induced models---there are chemically and/or surgically induced animal models of OA. Surgical models include damage to the anterior cruciate ligament and partial or complete menisectomy. These models have been validated in many species and consist of induced lesions similar to those observed in humans; therefore, it is expected that the disease will progress in a similar way to the progression of post-traumatic human OA. Some more aggressive surgical models are, however, not appropriate to study the effect of drugs targeting pain, because of the rapid progression of cartilage degeneration and slow and inconsistent development of pain-related behavior. Additionally, surgical models are often technically challenging. Nevertheless, surgical models have been used with great success, as seen in recent studies that looked at the pain mechanism in OA ([@B42]; [@B46]; [@B2]).

Chemically induced OA models, on the other hand, require much less intervention, consisting, normally, of a single intra-articular injection of substances, such as monoiodoacetate (MIA), papain, or mucilage, that can target different components of the joint ([@B32]; [@B43]). Because of their artificial onset, these models do not recapitulate the natural onset of the human disease but have, nevertheless, found pre-clinical value, namely because they originate robust and reproducible pain phenotypes, making them particularly adequate to test the efficacy of new pharmacological agents to treat OA pain ([@B6]; [@B43]). In addition, chemically induced models are easy to implement and require less invasive procedures than surgically induced models. Further, because of the fast onset of development of the pain phenotype---which can be controlled by controlling the dosage of the substances injected---they are much less expensive than spontaneous models. Of all OA models, the MIA model is the most often used, being commonly chosen to study the efficacy of pharmacological agents to treat pain ([@B6]; [@B15]).

The Monoiodoacetate Model {#s3}
=========================

MIA intra-articular injection results in histopathological alterations and functional impairment similar to some of the features observed in the early phases of human OA. MIA is an inhibitor of glyceraldehyde-3-phosphate, disrupting cellular glycolysis, which in turn leads to eventual cell death ([@B53]; [@B70]). Because the site of injection is restricted to the joint space, intra-articular injection of MIA causes mainly chondrocyte cell death, leading to cartilage degeneration and subsequent subchondral bone alterations ([@B19]; [@B28]). Although MIA can potentially affect different types of cells in the joint, the avascular nature of cartilage makes chondrocytes particularly vulnerable ([@B12]; [@B20]). While the method of induction is not technically challenging, MIA is highly toxic if it enters the circulation, quickly resulting in the animal's death, so care should be taken not to pierce the joint capsule during the injection, so as to prevent MIA from leaking outside of the joint.

Pathophysiology of MIA {#s4}
======================

Joint {#s4_1}
-----

Structurally, as early as 1 day after MIA injection, alterations to the surrounding synovium and articular cartilage have been described ([**Figure 1**](#f1){ref-type="fig"}) ([@B6]; [@B20]; [@B48]). Chondrocytes are shrunken with fragmented nuclei, and some areas of chondrocyte degeneration are present 1 to 3 days post-injection. The early stage of the model's progression is characterized by signs of inflammation such as synovial membrane expansion and infiltration of macrophages, neutrophils, mast cells, lymphocytes, and plasma cells, but they normally subside at day 7 ([**Figure 1**](#f1){ref-type="fig"}) ([@B68]). In accordance, human OA is also associated with synovitis, characterized by increased infiltration of macrophages and other immune cell types ([@B21]; [@B59]) as well as elevation of cytokine levels in synovial OA samples ([@B65]). Proximal structures such as the meniscus and ligaments also show signs of inflammation. In accordance, after MIA injection, an elevation of pro-inflammatory mediators such as Tumor Necrosis Factor-α (TNF-α) and Interleukin 6 (IL-6) is observed, typically peaking at day 4 ([@B48]). Clinically used NSAIDs given locally can reduce MIA-induced pain as well as MIA-induced C- and A-fiber spontaneous activity ([@B64]; [@B29]). Later stages of the disease (after day 10--14) are characterized by progressive cartilage degradation and remodeling of subchondral bone. Fourteen days post-injection, areas of full-thickness cartilage damage have been characterized. Formation of osteoclasts has also been described ([@B20]). There is also evidence of osteochondral angiogenesis and vascularization ([@B71]; [@B3]). Recently, it was also shown that superoxide dismutase mimetic compound MnIIMe2DO2A can reduce pain sensitivity and TNF-alpha serum levels in an MIA ankle model, suggesting a role of oxygen reactive species in the late stage of the model ([@B11]).

![Histopathological progression in the monosodium iodoacetate model of osteoarthritis. Top plane: Representative sections at different time points post--MIA injection (1 mg/mouse) stained with toluidine blue/purple, with femoral condyle at the top and tibial plateau at the bottom. (Left) Vehicle-injected joint with full-depth normal cartilage and normal subchondral bone structure. (Middle) Eleven days after MIA injection, visible focal cartilage damage and loss of proteoglycan staining (arrows) in both femoral and tibial condyles. (Right) Twenty-eight days after MIA injection, marked thinning of the whole articular surface, loss of proteoglycan staining, and restructuring of subchondral bone. Bottom plane: Representative sections at different time points post--MIA injection (1 mg/mouse) stained with hematoxylin and eosin. (Left) Vehicle-injected joint with normal synovium and few inflammatory cells visible. (Middle) At 11 days, there are obvious signs of inflammation: the synovial membrane is expanded, with a significantly increased density of inflammatory cells. (Right) At 28 days, inflammation is reduced, with a significant decrease in synovial size, but a dense cellularity is still observable. Scale bar = 100 µm.](fphar-10-00974-g001){#f1}

Primary Sensory Afferents {#s4_2}
-------------------------

The knee joint is innervated by primary sensory neurons (PSNs). Because cartilage is aneural, mechanisms independent of cartilage loss participate in mediating the initial pain in this model. However, in later stages, sensory nerves have been described to grow into the cartilage, along with new blood vessels ([@B3]). Nerve fibers detecting bone marrow lesions and edema have been shown to contribute to OA pain ([@B60]). PSN afferents can become sensitized by agents such as histamine or cytokines, underlying spontaneous pain, hyperalgesia, and allodynia following intra-articular MIA injection ([@B73]). In accordance, MIA induces a concentration-dependent increase of afferent responses to mechanical stimulation ([@B64]). Joint cells such as synoviocytes, inflammatory cells, or chondrocytes produce chemokines, cytokines, and proteases, which can sensitize PSN afferents ([@B61]). Li et al. have demonstrated that when dorsal root ganglia neurons are co-cultured with synovial fluid from OA patients, there is a clear elevation of genes associated with neuronal pathways (e.g., Substance P (SP), Neurokinin (NK1), Neurokinin (NK2), Neuropeptide y receptor (NPYR1), Neuropeptide y receptor (NPYR2), α2δ1) or inflammation Cyclooxygenase 2 (COX2)/Prostaglandin-endoperoxide synthase 2 (PTGS2) and IL-6/interferon β2), suggesting that blocking inflammation can be a way of modulating OA pain ([@B36]). Knee joints of both human and rodents are highly innervated by peptidergic afferents, i.e., they contain the peptides substance P and/or calcitonin gene-related peptide (CGRP) ([@B57]; [@B67]), and the number of CGRP-positive fibers in the joint is increased in the OA joint ([@B68]), a feature also observed in human hip OA ([@B58]). Consistently, there is an increase of CGRP content in the cell bodies of PSNs innervating the joint as well as an increase of CGRP release from the central terminals of PSNs ([@B14]; [@B16]; [@B68]). Further, peripheral blockade of CGRP receptors by inhibitor BIBN4096BS alleviates MIA-induced weight-bearing deficits ([@B22]). Nerve growth factor (NGF), which is an important trophic factor, is increased in OA joints ([@B26]; [@B41]), and pre-treatment with anti-NGF antibodies prevented the development of mechanical hypersensitivity in MIA-treated mice ([@B75]; [@B68]). Indeed, anti-NGF therapies have shown promising analgesic potential for OA pain treatment, with NGF antibodies showing efficacy for pain relief ([@B33]). Interestingly, NGF released from cells in the joint can increase CGRP and SP expression in Tropomyosin receptor kinase A (TrkA)-expressing neurons ([@B39]), potentially linking the roles of CGRP and NGF in OA pain ([@B39]; [@B47]; [@B68]).

Spinal Cord {#s4_3}
-----------

Primary afferent fibers of the knee joint project to several spinal cord segments and terminate in both the superficial and deeper laminae, where they synapse with dorsal horn neurons ([@B73]). Pathological changes in the joint cause these dorsal horn neurons to become hyperexcitable ([@B45]), reducing their thresholds and enhancing their responses to knee stimulation. Further, sensitized dorsal horn neurons expand their receptive fields, a mechanism that underlies the spread of hypersensitivity from the knee joint to adjacent areas. In accordance, MIA facilitates the responses of wide-dynamic-range (WDR) neurons to noxious and non-noxious stimulation ([@B9]). Further, MIA-induced increase in dorsal horn Fos immunoreactivity---a marker of neuronal activation---at both 7 and 28 days post--MIA injection correlates with behavioral outcomes ([@B68]). MIA-induced pain is also associated with increased phosphorylation of mitogen-activated protein kinases (MAPK) in the dorsal horn of the spinal cord, and MAPK1 inhibitor PD98059 blocked both MIA-induced pain behavior and phosphorilated extracellular signal-regulated kinases 1/2 (pERK1/2) induction in the spinal cord ([@B35]). The transient receptor potential vanilloid type 1 ion channel (TRPV1) is a polymodal transducer receptor expressed on a subset of PSNs that responds to various stimuli such as noxious heat, protons, and molecules such as capsaicin. It plays a crucial role in the development of burning pain and reflex hyperactivity across several models of pathological pain, including OA pain, where TRPV1 expression is elevated ([@B14]; [@B44]). Interestingly, TRPV1 activation modulates the firing of spinal nociceptive neurons in the MIA model, and blocking TRPV1 prevented spontaneous firing of WDR neurons ([@B9]). This mechanism involves the release of CGRP into the dorsal horn of the spinal cord ([@B52]), and consistently, intrathecal administration of CGRP antagonist CGRP8-37 ameliorates MIA-induced mechanical allodynia ([@B47]). Another important player modulating the afferent input into the dorsal horn is the endocannabinoid system, with various components of the system being elevated in the spinal cord of MIA-treated animals and anandamide catabolism blockade using Fatty acid amide hydrolase (FAAH) inhibitor URB597 having inhibitory effects in MIA-induced mechanically evoked responses of WDR neurons ([@B56]). Interestingly, endocannabinoid regulation of OA pain happens at multiple levels in the neuroaxis; in MIA-treated joints, local administration of Cannabinoid receptor 1 (CB1) receptor agonist Arachidonyl-2\'-chloroethylamide (ACEA) reduces the mechanosensitivity of afferent nerve fibers. This effect is reduced by blocking either Cannabinoid receptor 1 (CB1) receptor or TRPV1, suggesting that both receptors crosstalk in cannabinoid-mediated antinociception ([@B63]; [@B7]).

After MIA injection, a microglial response (microgliosis) in the ipsilateral dorsal horn, as well as microglia activation (p-p38 immunoreactivity), has been reported ([@B35]; [@B55]; [@B68]). Attenuation of microglial activation, *via* administration of glial inhibitor minocycline, is correlated with reduced pain behaviors in the MIA model ([@B55]). In contrast with the established role of microglia activation and proliferation in the development of the MIA model of OA, the participation of astrocytosis is less clear, with some studies reporting a lack of astrocyte response ([@B35]; [@B47]), while others studies report an increase of Glial fibrillary acidic protein (GFAP) immunoreactivity ([@B54]; [@B37]).

Neuropathic Component {#s5}
=====================

OA patients commonly complain of referred pain, i.e., pain in areas adjacent to the affected joint ([@B4]; [@B30]) and in a subset of OA patients who continue to feel pain even after a technically successful joint replacements ([@B38]). Both circumstances suggest the existence of a neuropathic component to OA pain, given that the pain arises in areas outside the injury site or after the peripheral nociceptive input has been removed altogether. In animal models, there are also signs of a neuropathic component; the aforementioned microglial activation observed during the development of the MIA model is often observed in different models of peripheral nerve damage. Further, expression of the peripheral nerve damage marker AMP-dependent transcription factor (ATF-3) in the Dorsal root ganglion (DRG) has been described in the MIA model ([@B17]; [@B69]). Pharmacologically speaking, gabapentin has been shown to have an analgesic effect in the late phase of the model, when NSAIDs appear to lose efficacy ([@B15]; [@B27]).

Behavior Profile of MIA {#s6}
=======================

In addition to structural changes, MIA-induced pain-related behavior has been characterized. Pain assessment in animals is challenging. Commonly used assays such as the von Frey test or the dynamic plantar aesthesiometer are used to measure alterations of nociceptive mechanical thresholds in the hind paw, rather than the injected knee joint---a measurement of referred pain. This is, primarily, because measuring such thresholds from the joint is technically challenging. Nevertheless, as mentioned above, during experimental OA, joint afferents typically expand their receptive fields to areas adjacent to the injecting joint. The same expansion of receptive fields and reduction of mechanical thresholds around the joint area have been observed in human OA patients ([@B72]; [@B13]; [@B31]). Another method commonly used is the incapacitance test, which measures the weight distribution between both hind limbs---a measurement of static pain ([@B6]). Weight-bearing asymmetry and paw withdrawal thresholds are measurements of ongoing pain and referred pain, respectively, and 1 mg MIA is the only dose to induce both, with 0.5 and 0.75 mg MIA only producing referred pain ([@B51]; [@B50]).

Interestingly, changes in the hind paw weight distribution closely followed changes in punctuate allodynia ([@B10]). MIA-induced pain-related behavior has a typical biphasic temporal profile ([@B51]; [@B50]). It usually manifests 1--3 days after administration as weight-bearing deficits and development of referred allodynia or hyperalgesia ([@B10]; [@B15]; [@B51]). This biphasic pattern is coincident with structural changes in the model progression, with the first stage associated with substantial inflammatory response and the second stage reflecting structural changes to the joint ([@B6]; [@B15]).

Pharmacology of MIA {#s7}
===================

The biphasic nature of the model can be also observed in the responsiveness of the model to pharmacological agents ([**Table 1**](#T1){ref-type="table"}). The initial stage of the pain phenotype is sensitive to paracetamol ([@B15]) and NSAIDs, which seems to correlate with signs of inflammation ([@B19]; [@B6]; [@B15]; [@B51]). This stage is followed by a later phase that is NSAID-insensitive where morphine, tramadol, and gabapentin are more efficacious, suggesting a neuropathic component at this stage, as mentioned above ([@B10]; [@B15]; [@B51]; [@B27]). This profile is somewhat different from the one observed in human patients, where a continuous although partial efficacy of NSAIDs is observed. Due to the responsiveness of this animal OA model, extensive pharmacological profiling has been employed to unveil new therapeutic targets to treat OA ([**Table 1**](#T1){ref-type="table"}).

###### 

Pharmacological modulation of pain-related behavior in MIA model of osteoarthritis.

  --------------------------------------------------------------------------------------------------------------------------------
  Compound            Dose (mg/kg)       Observed changes in pain-related behavior   References         
  ------------------- ------------------ ------------------------------------------- ------------------ --------------------------
  Diclofenac          30                 M.H.                                        --                 ([@B15])

  Morphine            6                  M.A., M.H.                                  M.H., M.A., W.B.   ([@B10]; [@B15]; [@B51])

  Gabapentin          6                  --                                          M.A., W.B          ([@B15]; [@B27])

  Paracetamol         1                  M.H.                                        W.B.               ([@B15])\
                                                                                                        ([@B6])

  Naproxen            10                 --                                          W.B.               ([@B6])

  Rofecoxib           10                 --                                          W.B.               ([@B6])

  Tramadol            3                  --                                          M.A., W.B.         ([@B10])

  CGRP8-37            5nmol/5 µl/mouse   --                                          M.A.               ([@B47])

  Indomethacin        3                  --                                          W.B.               ([@B51])

  Celecoxib           3                  --                                          W.B.               ([@B51])

  A-796260\*          35                 --                                          M.E.               ([@B76])

  URB597\*\*          5                  --                                          W.B.               ([@B62])

  PF-04457845         0.3                --                                          M.H.               ([@B1])

  Amitriptyline       3                  --                                          W.B.               ([@B27])

  A-889425\*\*\*      30                 --                                          M.E.               ([@B9])

  Anti-NGF antibody   5                  M.A.                                        --                 ([@B68])

  PD98059^+^          10 µl              --                                          M.E.               ([@B35])

  BIBN4096BS^++^      3                  W.B.                                        --                 ([@B22])

  Minocycline^+++^    30                 --                                          M.A                ([@B55])
  --------------------------------------------------------------------------------------------------------------------------------

M.A, referred mechanical hyperalgesia; measured with von Frey apparatus; M.H, mechanical hyperalgesia, measured with Randall--Salito; W.B, weight bearing, measured with incapacitance tester; M.E, movement-evoked pain, grip force test.

\*CB2 agonist.

\*\*FAAH inhibitor.

\*\*\*TRPV1 antagonist.

^+^MAPK1 inhibitor.

^++^CGRP antagonist.

^+++^glial cell inhibitor.

Conclusion {#s8}
==========

OA causes movement impairment and progressive disability, therefore impacting severely the quality of life ([@B5]; [@B8]). Given that aging and obesity are two of the main risk factors associated with OA, the prevalence is expected to increase by up to 50% in the future, highlighting the urgent need to find therapies to help manage OA ([@B23]; [@B49]; [@B25]). The MIA model of OA is a well-established and widely used chemical model of OA, being characterized by a robust and rapid pain phenotype, which can be graded by altering the MIA dosage. Despite the lack of correlation of the model with the pathogenesis of human OA, there is similarity between the changes that occur as consequence of MIA injection and those observed in human OA, namely, development of synovitis, progressive cartilage degeneration, and subchondral bone alterations. Additionally, over the last decades, several studies helped us gain insight into different pathological processes in play---from changes in the joint *per se* to alterations in sensory afferents projecting to the joints and to plasticity changes at the spinal cord level---making this model interesting in unraveling the biological mechanisms underlying the development of OA pain. Furthermore, pharmacological interventions commonly used in the clinic to treat OA pain such as NSAIDs or paracetamol have been found to also improve MIA-induced pain, reinforcing the translational potential of this model as a model to test the clinical efficacy of novel pharmacological tools.
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